Can BlissBio’s HER2-Targeting ADC Challenge Enhertu In Breast Cancer?
Eisai Deal Sets Stage For Battle
Executive Summary
A new deal worth up to $2bn-plus with Eisai has put Bliss Biopharmaceutical's HER2-targeting antibody-drug conjugate BB-1701 in the spotlight, as the global race heats up to find a possible challenger to Enhertu.
You may also be interested in...
Chinese Language Podcast: 重磅交易, 亚太药企如何度过资本寒冬, 减肥药风口
The latest China biopharma trends, including recent multimillion dollar deals by biotech firms, companies preparing for the worst as the 'capital winter' lingers, and GLP-1 agents for obesity are discussed by Brian Yang in Beijing and Dexter Yan in Shanghai in this latest Chinese-language podcast.
Asia Deal Watch: Aditum Bio Launches Vitalli To Develop Daewoong Immunology Candidate
In addition, deals involving Lupin/Medisol, Junshi/Dr. Reddy's, Zai Lab/MediLink, Kyowa Kirin/ADVANZ, Ipca/Unichem, Jiangsu Aidea/Kainos.
Deal Watch: Gilead Grows Oncology, Inflammation Pipeline With XinThera Buy
The XinThera deal gives Gilead multiple PARP1 and MK2 inhibitors. Also, Roche licenses a HER2 kinase inhibitor from Zion, Amgen partners with TScan in Crohn’s disease and Baxter sells the last of its biopharma operations – a CDMO business – for $4.5bn.